Outlook Therapeutics, Inc. shares fall 1.95% premarket as Wall Street futures mixed ahead of inflation data.

Outlook Therapeutics, Inc. declined 1.95% in premarket trading. The stock's movement aligns with the mixed sentiment in the market as investors await key inflation data that could sway bets on interest rate cuts. Additionally, the market has been on edge all week, with traders recalibrating odds on further rate reductions amid economic data and mixed commentary from the Federal Reserve's policymakers.